Necuparanib - Momenta Pharmaceuticals

Drug Profile

Necuparanib - Momenta Pharmaceuticals

Alternative Names: M-402; M-ONC 402; M402 heparan sulfate

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Antineoplastics; Glycosaminoglycans; Sugar alcohols; Uronic acids
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 04 Aug 2016 Momenta discontinues patient enrolment in a phase II trial in Pancreatic cancer (Combination therapy, Late-stage) due to lack of efficacy data
  • 04 Jun 2016 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in pancreatic cancer (First line therapy, Combination therapy, Metastatic disease) presented at the American Society of Clinical Oncology Annual meeting (ASCO-2016)
  • 21 Dec 2015 Momenta Pharmaceuticals re-initiates enrolment in the phase II MOM-M402-103 trial for Pancreatic cancer (First line therapy, Combination therapy, Metastatic disease) in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top